Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (15117)	1/5/2005 7:22:15 PM
From: Stephen O	Read Replies (1) \| Respond to of 52153

That's exactly my point. Reduce the inflammation without using a harsh drug to monkey with the liver's production of cholesterol. Cholesterol is used in the body's chemistry to repair myelin sheathing, nerves, brain cells, testosterone production etc etc. If such a drug or process appears then we don't need statins. Sayonara Lipitor. Remember 50% of heart attacks occur in people with low or normal cholesterol. What is this board's opinion of Vasogen and the way it operates?

To: Biomaven who wrote (15117)	1/6/2005 2:58:47 PM
From: Rudy Saucillo	Read Replies (1) \| Respond to of 52153

Curious that these studies didn't address the correlation of other known inflammation markers with CV events. "Acute Coronary Syndrome and Inflammation. Biomarkers for Diagnostics and Risk Stratification." ncbi.nlm.nih.gov For example, myeloperoxidase (mentioned in the above abstract) was reduced by statistically significant amounts in the AGIX CART II treatment group. Corresponding plaque reduction in the treatment group was statistically significant w.r.t. baseline and w.r.t. SOC in the 10mm most diseased segments. One reason CRP is studied extensively appears to be ease of measurement: "CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: clinical use of inflammatory markers in patients with cardiovascular diseases: a background paper." ncbi.nlm.nih.gov Interestingly, myeloperoxidase is also associated with kidney disease: "Myeloperoxidase in kidney disease" ncbi.nlm.nih.gov "Are advanced oxidation protein products potential uremic toxins?" ncbi.nlm.nih.gov